Since the FDA declared the Ozempic and Wegovy shortage resolved on February 21, 2025, pharmacies had to stop making compounded versions: State-licensed pharmacies stopped by April 22, 2025 Outsourcing facilities stopped by May 22, 2025 This leaves only the brand-name options available, but with the new pricing through Medicare and TrumpRx, access is actually better than it was with compounded versions for many patients
BPI Labs offers competitive pricing with growing test data
This represents a substantial reduction in per-injection device cost, contributing to a lower total cost of ownership for B2B entities
verify current status with Sunlight before enrolling What requires independent confirmation or can't be verified by this publication: 100,000+ patient count - brand-reported, not audited 98% patient success rate - brand-reported from self-reported data Specific patient outcomes cited in testimonials - self-reported individual experiences Current LegitScript certification status - check directly at legitscript.com Current pharmacy compounding compliance with 2026 FDA guidance - verify directly with Sunlight before enrolling Current pricing at time of enrollment - may change
This is appropriate for sedentary individuals or people with higher body fat percentages